Clinical Trial Update: Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study [Phase 2]

View source ↗

Summary

A Phase II neoadjuvant study in ER+/PgR+ breast cancer completed, evaluating Arimidex (anastrozole) with or without Iressa (gefitinib).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ARIMIDEX (anastrozole)
• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED